The TRAVERSE trial showed testosterone replacement treatment was noninferior to placebo with regard to the risk of major adverse cardiac events. The Food and Drug Administration (FDA) is requiring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results